Screener
Gilead Sciences GILD Descovy — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Product sales: | ||||||||
| HIV | ||||||||
| Biktarvy | $2,981 | $468 | $323 | $3,772 | $2,799 | $429 | $302 | $3,530 |
| Descovy | 921 | 23 | 23 | 967 | 601 | 24 | 28 | 653 |
| Genvoya | 236 | 37 | 16 | 289 | 322 | 40 | 16 | 377 |
| Odefsey | 171 | 58 | 10 | 239 | 221 | 66 | 11 | 298 |
| Symtuza - Revenue share(1) | 105 | 30 | 3 | 138 | 88 | 33 | 3 | 124 |
| Yeztugo | 223 | — | 9 | 232 | 15 | — | — | 15 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's descovy — total revenues?
- Gilead Sciences (GILD) reported descovy — total revenues of $967M in Q2 2026.
- How has Gilead Sciences's descovy — total revenues changed year-over-year?
- Gilead Sciences's descovy — total revenues increased by 48.1% year-over-year, from $653M to $967M.
- What is the long-term trend for Gilead Sciences's descovy — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's descovy — total revenues has grown at a 12.9% compound annual growth rate (CAGR), from $1.7B to $2.76B.
- What does descovy — total revenues mean?
- This metric represents the total gross revenue generated from the sales of a specific HIV treatment product line. It reflects the market adoption, pricing power, and competitive positioning of the therapy within the broader infectious disease portfolio. Tracking this revenue stream provides insight into the sustainability of the company's core HIV franchise and the impact of patent lifecycles or therapeutic competition.
Ask your AI about Gilead Sciences's descovy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude